|
Synonyms: DNTH-103 | DNTH103 | IgG4-MAB39 [US12110344] | MAB39 [US12110344]
Compound class:
Antibody
Comment: Claseprubart (DNTH103) is a long-acting monoclonal antibody that selectively inhibits the active form of the C1s (complement component 1s) protein in the classical complement pathway.
Peptide sequences for the heavy and light chains of claseprubart are 100% matches for sequences for MAB39 that are claimed in patent US12110344B2 [1]. Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use ![]() |
| Claseprubart (DNTH103) was progressed as a clinical candidate for the treatment of severe autoimmune and neuromuscular diseases. Studies were initiated for generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. The FDA granted orphan designation for the treatment of myasthenia gravis in May 2026 [2]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06282159 | A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC) | Phase 2 Interventional | Dianthus Therapeutics | ||
| NCT06537999 | A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy | Phase 2 Interventional | Dianthus Therapeutics | ||
| NCT06858579 | A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) | Phase 3 Interventional | Dianthus Therapeutics | ||
| NCT07647510 | A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE) | Phase 3 Interventional | Dianthus Therapeutics | ||